MedCity News January 15, 2025
More than a decade ago, Medtronic announced that a pivotal trial testing its renal denervation system had failed. Though the system was later approved by the FDA, reimbursement has been elusive. All that might change this year.
At the 43rd annual J.P. Morgan Healthcare Conference on Monday, Medtronic CEO Geoff Martha mixed in some breaking news with his usual pitch to investors. Just hours earlier, the Centers for Medicare and Medicaid Services (CMS) had informed the company that it was opening a national coverage analysis of renal denervation and a final decision will be forthcoming after the review concludes on October 11, 2025.
“Our Symplicity blood pressure procedure is poised to transform hypertension management, and it’s a large opportunity that’s...
Today's Sponsors
Today's Sponsor